Chain-length specific ceramide biology in cardiovascular disease: from molecular diversity to precision risk stratification

Ceramides are increasingly recognized as biomarkers and potential mediators of residual cardiovascular risk, yet their biological significance cannot be captured by total ceramide abundance alone. Individual species differ in acyl-chain length, saturation, enzymatic origin, tissue distribution, and subcellular localization, resulting in distinct and sometimes opposing cardiovascular effects. This review synthesizes biochemical, experimental, clinical, and genetic evidence through a chain-length specific framework. Long-chain ceramides, particularly Cer16:0 and Cer18:0, are consistently associated with lipotoxicity, mitochondrial dysfunction, impaired insulin signaling, endothelial injury, inflammation, plaque instability, myocardial remodeling, and adverse cardiovascular outcomes. In contrast, saturated very-long-chain species such as Cer22:0 and Cer24:0 often define a lower-risk circulating profile, although their effects remain tissue- and disease-dependent; Cer24:1 further demonstrates that saturation modifies the biological meaning of chain length. These patterns explain the prognostic value of ratios such as Cer16:0/Cer24:0 and Cer18:0/Cer24:0 and provide a biological basis for CERT1 and CERT2. We further examine ceramide synthases as determinants of species composition, distinguish circulating biomarkers from tissue-level mechanisms, and evaluate emerging genetic, causal, and therapeutic evidence. Collectively, current data support a precision lipidomic model focused on pathogenic chain-length remodeling rather than non-selective suppression of total ceramides.